These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24521036)

  • 1. Craving predicts opioid use in opioid-dependent patients initiating buprenorphine treatment: a longitudinal study.
    Tsui JI; Anderson BJ; Strong DR; Stein MD
    Am J Drug Alcohol Abuse; 2014 Mar; 40(2):163-9. PubMed ID: 24521036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.
    Northrup TF; Stotts AL; Green C; Potter JS; Marino EN; Walker R; Weiss RD; Trivedi M
    Addict Behav; 2015 Feb; 41():20-8. PubMed ID: 25282598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.
    Kowalczyk WJ; Phillips KA; Jobes ML; Kennedy AP; Ghitza UE; Agage DA; Schmittner JP; Epstein DH; Preston KL
    Am J Psychiatry; 2015 Aug; 172(8):760-7. PubMed ID: 25783757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy.
    Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Edwards RR; Samet JH
    Drug Alcohol Depend; 2016 Sep; 166():26-31. PubMed ID: 27422763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients.
    McHugh RK; Fitzmaurice GM; Carroll KM; Griffin ML; Hill KP; Wasan AD; Weiss RD
    Drug Alcohol Depend; 2014 Dec; 145():121-6. PubMed ID: 25454409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder.
    Shcherbakova N; Tereso G; Spain J; Roose RJ
    Ann Pharmacother; 2018 May; 52(5):405-414. PubMed ID: 29302989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
    Saleh MI
    Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and patients with chronic pain using opioids nonmedically.
    Suzuki J; Matthews ML; Brick D; Nguyen MT; Wasan AD; Jamison RN; Ellner AL; Tishler LW; Weiss RD
    J Opioid Manag; 2014; 10(3):159-68. PubMed ID: 24944066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
    Evans EA; Zhu Y; Yoo C; Huang D; Hser YI
    Addiction; 2019 Aug; 114(8):1396-1404. PubMed ID: 30916463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower buprenorphine elimination rate constant is associated with lower opioid use.
    Elarabi HF; Lee AJ; Adem A; Elrasheed A; Marsden J; Al Ghaferi H
    Psychopharmacology (Berl); 2022 Oct; 239(10):3213-3221. PubMed ID: 35953563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gradual dose taper following chronic buprenorphine.
    Becker AB; Strain EC; Bigelow GE; Stitzer ML; Johnson RE
    Am J Addict; 2001; 10(2):111-21. PubMed ID: 11444154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of behavioral treatment conditions in buprenorphine maintenance.
    Ling W; Hillhouse M; Ang A; Jenkins J; Fahey J
    Addiction; 2013 Oct; 108(10):1788-98. PubMed ID: 23734858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine-naloxone maintenance following release from jail.
    Lee JD; Grossman E; Truncali A; Rotrosen J; Rosenblum A; Magura S; Gourevitch MN
    Subst Abus; 2012; 33(1):40-7. PubMed ID: 22263712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-buprenorphine opioid utilization among patients using buprenorphine.
    Daubresse M; Saloner B; Pollack HA; Alexander GC
    Addiction; 2017 Jun; 112(6):1045-1053. PubMed ID: 28107580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.
    Edelman EJ; Chantarat T; Caffrey S; Chaudhry A; O'Connor PG; Weiss L; Fiellin DA; Fiellin LE
    Drug Alcohol Depend; 2014 Jun; 139():79-85. PubMed ID: 24726429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.